| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-01 | Celgene (USA - NJ) | nomination |
Cancer - Oncology - Inflammatory diseases | Nomination | ||
| 2015-04-01 | Amag Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2015-03-31 | The Lead Discovery Center (LDC) (Germany) Helmholtz Centre for Infection Research (HZI) (Germany) | new drug candidates against methicillin-resistant Staphylococcus aureus | methicillin-resistant Staphylococcus aureus (MRSA) infections | R&D |
Infectious diseases | R&D agreement |
| 2015-03-31 | Tyrogenex (USA - Fl) | nomination |
Cancer - Oncology - Ophtalmological diseases | Nomination | ||
| 2015-03-31 | Broad Institute of MIT and Harvard (USA - MA) Bayer Healthcare (Germany) | cardiovascular genomics | cardiovascular diseases | collaboration R&D |
Cardiovascular diseases | Collaboration agreement |
| 2015-03-31 | Redhill Biopharma (Israel) Apogee Biotechnology (USA - PA) | ABC294640 | licensing |
Cancer - Oncology - Gastrointestinal diseases - Digestive diseases | Licensing agreement | |
| 2015-03-31 | Sarepta Therapeutics (USA - MA) | nomination |
Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | ||
| 2015-03-30 | Aduro Biotech (USA - CA) Novartis (Switzerland) | ADU-S100 and novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor | R&D - development - commercialisation | Cancer - Oncology | Research agreement | |
| 2015-03-30 | BioInvent (Sweden) Cancer Research Technology (CRT) (UK) University of Southampton (UK) | antibodies targeting OX40 and 4-1BB | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-03-30 | Abbvie (USA - IL) Biomed X (Germany) | Alzheimer\'s disease | collaboration R&D |
Neurodegenerative diseases | Collaboration agreement | |
| 2015-03-30 | Ziopharm Oncology (USA - MA) Intrexon (USA - MD) Merck KGaA (Germany) | chimeric antigen receptor T-cell (CAR-T) products | collaboration R&D |
Cancer - Oncology | Collaboration agreement | |
| 2015-03-30 | Therametrics (Switzerland) Centurion Pharma (Turkey) | aviptadil | sarcoidosis | licensing collaboration |
Inflammatory diseases | Licensing agreement |
| 2015-03-27 | Morphosys (Germany) Celgene (USA) | MOR202 (anti CD38 antibody) | multiple myeloma and other indications | development |
Cancer - Oncology | Termination of an agreement |
| 2015-03-27 | Atara Biotherapeutics (USA - CA) | nomination |
Cancer - Oncology - Kidney diseases - Renal diseases | Nomination | ||
| 2015-03-27 | RXi Pharmaceuticals (USA - MA) MirImmune (USA - MA) | sd-rxRNA® technology for use in developing innovative cell-based cancer immunotherapies | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-03-26 | Inventiva (France) SensiQ Technologies (USA - OK) | SPR Center of Excellence | opening of new premises | Technology - Services | Opening of new premises | |
| 2015-03-26 | Philips (The Netherlands) Leiden University Medical Center (The Netherlands) | personalized coaching solutions using wearable sensors | R&D collaboration |
R&D agreement | ||
| 2015-03-26 | Biocartis (Belgium) Microbiome (The Netherlands) | multiplex real-time PCR assay for rapid detection of bloodstream infections | bloodstream infections | collaboration licensing |
Diagnostic - Infectious diseases | Licensing agreement |
| 2015-03-26 | Erytech Pharma (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-26 | Shire (UK - USA) Cincinnati Children’s Hospital Medical Center (USA - OH) | R&D |
Rare diseases | R&D agreement |
